224 related articles for article (PubMed ID: 31356143)
21. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
[TBL] [Abstract][Full Text] [Related]
22. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Duval L; Schmidt H; Kaltoft K; Fode K; Jensen JJ; Sorensen SM; Nishimura MI; von der Maase H
Clin Cancer Res; 2006 Feb; 12(4):1229-36. PubMed ID: 16489078
[TBL] [Abstract][Full Text] [Related]
23. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
24. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
25. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
[TBL] [Abstract][Full Text] [Related]
26. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
27. The Role of Antigen Spreading in the Efficacy of Immunotherapies.
Brossart P
Clin Cancer Res; 2020 Sep; 26(17):4442-4447. PubMed ID: 32357962
[TBL] [Abstract][Full Text] [Related]
28. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
29. Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.
Horn T; Grab J; Schusdziarra J; Schmid S; Maurer T; Nawroth R; Wolf P; Pritsch M; Gschwend JE; Kübler HR; Beckhove P
Int J Cancer; 2013 Nov; 133(9):2145-56. PubMed ID: 23625723
[TBL] [Abstract][Full Text] [Related]
30. Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.
Shah PD; Huang AC; Xu X; Orlowski R; Amaravadi RK; Schuchter LM; Zhang P; Tchou J; Matlawski T; Cervini A; Shea J; Gilmore J; Lledo L; Dengel K; Marshall A; Wherry EJ; Linette GP; Brennan A; Gonzalez V; Kulikovskaya I; Lacey SF; Plesa G; June CH; Vonderheide RH; Mitchell TC
Cancer Res Commun; 2023 May; 3(5):821-829. PubMed ID: 37377890
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
32. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
33. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
Meidenbauer N; Marienhagen J; Laumer M; Vogl S; Heymann J; Andreesen R; Mackensen A
J Immunol; 2003 Feb; 170(4):2161-9. PubMed ID: 12574389
[TBL] [Abstract][Full Text] [Related]
34. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
Front Immunol; 2018; 9():1971. PubMed ID: 30233577
[TBL] [Abstract][Full Text] [Related]
35. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
Li J; Mookerjee B; Wagner J
J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
[TBL] [Abstract][Full Text] [Related]
36. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
37. Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide.
Gold JE; Malamud SC; LaRosa F; Seder R; Osband ME
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):213-21. PubMed ID: 8471596
[TBL] [Abstract][Full Text] [Related]
38. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
39. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.
Kawashima I; Hudson SJ; Tsai V; Southwood S; Takesako K; Appella E; Sette A; Celis E
Hum Immunol; 1998 Jan; 59(1):1-14. PubMed ID: 9544234
[TBL] [Abstract][Full Text] [Related]
40. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
